Clinical trials: Nasopharyngeal Cancer Recurrent
Nasopharyngeal Carcinoma
Chemoradiotherapy Plus Anti-PD1 in Recurrent NPC: A Multicenter, Open-label, Randomised, Controlled, Phase III Trial
This is a multicenter, open-label, randomized, controlled, phase III trial. The purpose of this trial is to evaluate the efficacy and toxicity of anti-PD-1 antibody combined with chemoradiotherapy versus chemoradiotherapy alone…
- Trial name
- NCT05340491
- Testing
- Toripalimab, Chemotherapy, Intensity modulated radiotherapy
- Where
- 12 sites in China
- Volunteers
- 212 people
- Sponsor
- Sun Yat-sen University
Renal Cell Carcinoma, Nasopharyngeal Carcinoma
Trial of PRO1160 (GEN1160) in Relapsed or Refractory Non-Hodgkin Lymphoma (NHL) (PRO1160-001)
Brief Summary: This study will test the safety, including side effects, and determine the characteristics of a drug called GEN1160 (PRO1160) in participants with solid tumors and blood cancers.
- Conditions
- Renal Cell Carcinoma, Nasopharyngeal Carcinoma, Non Hodgkin Lymphoma
- Trial name
- NCT05721222
- Testing
- GEN1160
- Where
- 17 sites in United States, China
- Volunteers
- 42 people
- Sponsor
- Genmab
Malignant Head and Neck Neoplasm, Malignant Neoplasm
Association Between Health Care Provider (HCP)-Assessed ECOG Performance Status (PS) and Overall Survival, and Objectively Measure of Physical Activity (PA) Levels in Advance-cancer Patients"
The main goal of this phase of the study is to determine if objectively assessed Physical Activity (PA) levels in advanced-cancer patients are associated with health care provider (HCP)-assessed ECOG performance status and…
- Conditions
- Malignant Head and Neck Neoplasm, Malignant Neoplasm, Metastatic Malignant Neoplasm in the Neck, Metastatic Malignant Neoplasm in the Uterine Cervix
- Trial name
- NCT01365169
- Testing
- Exercise Intervention, Health Telemonitoring, Quality-of-Life Assessment
- Where
- United States
- Volunteers
- 590 people
- Sponsor
- M.D. Anderson Cancer Center
Nasopharyngeal Carcinoma, Toripalimab
Concurrent Chemoradiotherapy With Toripalimab for Local-regional Recurrent Nasopharyngeal Carcinoma: a Prospective, Single-arm, Phase II Trial
This is a prospective, single-arm, phase II trial to study the efficacy of PD-1 antibody Toripalimab combined with concurrent cisplatin chemoradiotherapy in treating patients with locoregionally recurrent nasopharyngeal carcinoma.
- Conditions
- Nasopharyngeal Carcinoma, Toripalimab, Recurrent Nasopharyngeal Squamous Cell Carcinoma
- Trial name
- NCT04992988
- Testing
- Toripalimab
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Cancer Hospital of Guangxi Medical University
Head and Neck Squamous Cell Carcinoma
Clinical Trial of SIBP-03 in Patients With Head and Neck Squamous Cell Carcinoma
This phase II study will be conducted in two parts (Ⅱa and Ⅱb), with a 21-day treatment cycle until disease progression, intolerable toxicity, withdrawal of informed consent, death, initiation of new anti-tumor treatment or loss…
- Trial name
- NCT06194656
- Testing
- HER3 Monoclonal antibodies-Dose A, HER3 Monoclonal antibodies-Dose B, HER3 Monoclonal antibodies-Dose C
- Where
- 2 sites in China
- Volunteers
- 81 people
- Sponsor
- Shanghai Institute Of Biological Products
Nasopharyngeal Carcinoma
A Phase III Study of YL201 in Recurrent or Metastatic Nasopharyngeal Carcinoma (TAISHAN-301)
This study was designed to compare the efficacy and safety of YL201 with Investigator's choice of chemotherapy in subjects with recurrent or metastatic nasopharyngeal carcinoma who have failed prior PD-(L)1 inhibitor and at least…
- Trial name
- NCT06629597
- Testing
- YL201, Docetaxel, Capecitabine
- Where
- China
- Volunteers
- 400 people
- Sponsor
- MediLink Therapeutics (Suzhou) Co., Ltd.
Recurrent or Metastatic Nasopharyngeal Carcinoma
Clinical Study of Mitoxantrone Hydrochloride Liposome Combined with PD-1 Blockade in Recurrent or Metastatic NPC
This is a prospective, single-arm Phase 2 study to evaluate the efficacy and safety of mitoxantrone hydrochloride liposome injection combined with PD-1 blockade in patients with recurrent (not unable to locally curative…
- Trial name
- NCT06472713
- Testing
- Mitoxantrone hydrochloride liposome injection, PD-1 Inhibitors
- Where
- China
- Volunteers
- 32 people
- Sponsor
- Ming-Yuan Chen
Nasopharyngeal Carcinoma
SHR-1701 in Patients With Recurrent/Metastatic Nasopharyngeal Carcinoma
This is an open label, phase Ib Study of SHR-1701 in patients with recurrent/metastatic nasopharyngeal carcinoma(R/M NPC).
- Trial name
- NCT04282070
- Testing
- SHR-1701, Gemcitabine, Cisplatin
- Where
- China
- Volunteers
- 91 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma, Recurrent Adenoid Cystic Carcinoma of the Oral Cavity
Erlotinib and Cetuximab With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Kidney, Colorectal, Head and Neck, Pancreatic, or Non-Small Cell Lung Cancer
This randomized phase I/II trial studies the side effects, best way to give, and best dose of erlotinib and bevacizumab when given with cetuximab and how well giving erlotinib and cetuximab together with or without bevacizumab…
- Conditions
- Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma, Recurrent Adenoid Cystic Carcinoma of the Oral Cavity, Recurrent Basal Cell Carcinoma of the Lip, Recurrent Colon Cancer
- Trial name
- NCT00101348
- Testing
- erlotinib hydrochloride, cetuximab, bevacizumab
- Where
- United States
- Volunteers
- 66 people
- Sponsor
- National Cancer Institute (NCI)
Nasopharyngeal Carcinoma
A Phase II Trial of S-1 as Maintenance Treatment After Gemcitabine Plus Cisplatin Regimen Chemotherapy in Patients With Recurrent and/or Metastatic Nasopharyngeal Carcinoma.
A Phase II Trial of S-1 as Maintenance Treatment After Gemcitabine Plus Cisplatin Regimen Chemotherapy in Patients With Recurrent and/or Metastatic Nasopharyngeal Carcinoma.
- Trial name
- NCT02878889
- Testing
- S-1
- Where
- 2 sites in China
- Volunteers
- 53 people
- Sponsor
- Zhejiang Cancer Hospital
Recurrent Hypopharyngeal Squamous Cell Carcinoma, Recurrent Laryngeal Squamous Cell Carcinoma
Cediranib Maleate in Treating Patients With Recurrent or Newly Diagnosed Metastatic Head and Neck Cancer
This phase II trial is studying how well cediranib maleate works in treating patients with recurrent or newly diagnosed metastatic head and neck cancer.
- Conditions
- Recurrent Hypopharyngeal Squamous Cell Carcinoma, Recurrent Laryngeal Squamous Cell Carcinoma, Recurrent Laryngeal Verrucous Carcinoma, Recurrent Lip and Oral Cavity Squamous Cell Carcinoma
- Trial name
- NCT00458978
- Testing
- Cediranib Maleate, Laboratory Biomarker Analysis
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- National Cancer Institute (NCI)
Nasopharyngeal Carcinoma
BGT007 Cell Treatment of Nasopharyngeal Carcinoma
This is an exploratory study to evaluate the safety and preliminary effectiveness of BGT007 cells in the treatment of recurrent/metastatic nasopharyngeal carcinoma
- Trial name
- NCT05616468
- Testing
- BGT007 Cell Injection, Fludarabine, cyclophosphamide
- Where
- China
- Volunteers
- 23 people
- Sponsor
- The Affiliated Hospital of Xuzhou Medical University
Paranasal Sinus Squamous Cell Carcinoma, Recurrent Hypopharyngeal Squamous Cell Carcinoma
Capecitabine and Vorinostat in Treating Patients With Recurrent and/or Metastatic Head and Neck Cancer
This partially randomized phase II trial studies giving capecitabine and vorinostat in treating patients with head and neck cancer that has come back after previous treatment or that has spread to other areas in the body.
- Conditions
- Paranasal Sinus Squamous Cell Carcinoma, Recurrent Hypopharyngeal Squamous Cell Carcinoma, Recurrent Laryngeal Squamous Cell Carcinoma, Recurrent Oral Cavity Squamous Cell Carcinoma
- Trial name
- NCT01267240
- Testing
- Capecitabine, Vorinostat
- Where
- 14 sites in United States, Canada
- Volunteers
- 25 people
- Sponsor
- National Cancer Institute (NCI)
Nasopharyngeal Carcinoma
Pembrolizumab and Olaparib in Recurrent/Metastatic, Platinum Resistant Nasopharyngeal Cancer
Recurrence rate after curative treatment for locally advanced Nasopharyngeal carcinoma (NPC) is reported varying from 15% to 30% of cases, while approximately 5-11% of patients present with de novo metastatic disease.
- Trial name
- POINT (NCT04825990)
- Testing
- Pembrolizumab
- Where
- Italy
- Volunteers
- 30 people
- Sponsor
- Gruppo Oncologico del Nord-Ovest
Metastatic Nasopharyngeal Carcinoma, Recurrent Nasopharyngeal Carcinoma
Testing Nivolumab and Ipilimumab Immunotherapy With or Without the Targeted Drug Cabozantinib in Recurrent, Metastatic, or Incurable Nasopharyngeal Cancer
This phase II trial tests how well nivolumab and ipilimumab immunotherapy with or without cabozantinib works in treating patients with nasopharyngeal cancer that has come back (after a period of improvement) (recurrent), has…
- Conditions
- Metastatic Nasopharyngeal Carcinoma, Recurrent Nasopharyngeal Carcinoma, Stage IV Nasopharyngeal Carcinoma AJCC v8
- Trial name
- NCT05904080
- Testing
- Biospecimen Collection, Cabozantinib S-malate, Computed Tomography
- Where
- 92 sites in United States
- Volunteers
- 50 people
- Sponsor
- National Cancer Institute (NCI)
Head and Neck Cancer
Cetuximab and Stereotactic Radiation Therapy in Treating Patients With Recurrent Head and Neck Cancer That Cannot Be Removed By Surgery
RATIONALE: Monoclonal antibodies, such as cetuximab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread.
- Trial name
- CKNO-RERT (NCT00738868)
- Testing
- cetuximab, stereotactic body radiation therapy
- Where
- France
- Volunteers
- 45 people
- Sponsor
- Centre Oscar Lambret
Head and Neck Cancer, Long-term Effects Secondary to Cancer Therapy in Adults
Side Effects of High-Dose Intensity-Modulated Radiation Therapy in Treating Patients With Advanced Head and Neck Cancer
RATIONALE: Tests that measure how much saliva is made, hearing, swallowing, voice function, and quality of life may improve the ability to plan treatment for patients with advanced head and neck cancer and may help doctors find…
- Conditions
- Head and Neck Cancer, Long-term Effects Secondary to Cancer Therapy in Adults, Oral Complications of Radiation Therapy, Radiation Toxicity
- Trial name
- NCT00415025
- Testing
- adjuvant therapy, management of therapy complications, quality-of-life assessment
- Volunteers
- 20 people
- Sponsor
- University of Wisconsin, Madison
Mucositis, Oral Complications of Chemotherapy
L-lysine in Treating Oral Mucositis in Patients Undergoing Radiation Therapy With or Without Chemotherapy For Head and Neck Cancer
This pilot clinical trial studies L-lysine in treating oral mucositis in patients undergoing radiation therapy with or without chemotherapy for head and neck cancer.
- Conditions
- Mucositis, Oral Complications of Chemotherapy, Oral Complications of Radiation Therapy, Recurrent Adenoid Cystic Carcinoma of the Oral Cavity
- Trial name
- NCT01155609
- Testing
- quality-of-life assessment, management of therapy complications, L-lysine
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- University of Washington
Head and Neck Cancer, Infection
Fluconazole in Preventing Mucositis in Patients Undergoing Radiation Therapy for Head and Neck Cancer
RATIONALE: Giving fluconazole may be effective in preventing or controlling mucositis caused by radiation therapy to the head and neck.
- Conditions
- Head and Neck Cancer, Infection, Oral Complications
- Trial name
- NCT00002533
- Testing
- fluconazole, radiation therapy
- Where
- United States
- Sponsor
- University of Miami
Nasopharyngeal Neoplasms, Mortality
Hyperfractionated Intensity-modulated Radiotherapy (IMRT) Versus Conventional Fraction IMRT for Patients With Loco-regionally Recurrent Nasopharyngeal Carcinoma.
This study evaluates the hyperfractionated IMRT in the treatment of patients with locally recurrent nasopharyngeal carcinoma. Half of participants will receive hyperfractionated IMRT, while the other half will receive…
- Conditions
- Nasopharyngeal Neoplasms, Mortality, Quality of Life, Complications
- Trial name
- NCT02456506
- Testing
- Hyperfractionated IMRT, Conventional Fraction IMRT
- Where
- China
- Volunteers
- 142 people
- Sponsor
- Sun Yat-sen University